PK
Insider
Paul Edward Kelly
Chief Operating OfficerPaul Edward Kelly (Chief Operating Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Relmada Therapeutics, Inc. (RLMD). Across 1 priced purchase filing, the average 21-session return was +56.9% from execution and +48.8% from disclosure (delay-adjusted; derived). The largest single filing was $198K of RLMD (90,000 sh × $2.20, as filed), executed Nov 5 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+56.9%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+48.8%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$198K
shares × price, as filed
Last traded
Nov 5 2025
Filed Nov 6 2025
Median ADV $7.1M across their filed names
Open performance→Volume by month
Buys $198K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
RLMDRecent filings
RLMDPURCHASE
Relmada Therapeutics, Inc.
View filing →
$198K90,000 sh × $2.20
Exec Nov 5 2025
Filed Nov 6 2025 · 7:30 AM ET